PDS Biotech Announces Virtual KOL Event for PDS0301
PDS Biotechnology (PDSB) will host a virtual event to present clinical data for its PDS0301 Phase 2 trials in advanced colorectal liver metastases. This advancement could support immunotherapy efficacy for the MSS patient population, where current treatments are largely ineffective.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed